Clinical Trials in Tennessee

Showing 2661-2680 of 9,675 trials

Open-Label Extension Study of DCCR in Patients With Prader-Willi Syndrome

NCT05701774

The purpose of this is study is to evaluate the long-term safety of DCCR (diazoxide choline) extended-release tablets) in patients with Prader-Willi syndrome.

Prader-Willi Syndrome

Soleno Therapeutics, Inc.83 participantsStarted Jan 2023

Orange, California, United States • Palo Alto, California, United States • San Diego, California, United States +19 more locations

Active Not RecruitingPhase 1/229 miles

EDIT-301 for Autologous Hematopoietic Stem Cell Transplant (HSCT) in Participants With Transfusion-Dependent Beta Thalassemia (TDT)

NCT05444894

The purpose of this study is to evaluate the safety, tolerability, and efficacy of treatment with EDIT-301 in adult participants with Transfusion Dependent beta Thalassemia

Transfusion Dependent Beta ThalassemiaHemoglobinopathiesThalassemia Major+1 more

Editas Medicine, Inc.9 participantsStarted Apr 2022

Oakland, California, United States • Minneapolis, Minnesota, United States • New York, New York, United States +5 more locations

Open-Label Extension Study of DCCR in Patients With Prader-Willi Syndrome

EDIT-301 for Autologous Hematopoietic Stem Cell Transplant (HSCT) in Participants With Transfusion-Dependent Beta Thalassemia (TDT)

Find Trials by Condition in Tennessee

SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas

Strategy to Avoid Excessive Oxygen in Major Burn Patients

Clinical Safety and Efficacy of Infrared Neural Stimulation During Nerve Transfers

Testing the Effect of the Youth Mindful Awareness Program on Negative Affect

Maximizing Outcomes for Preschoolers With Developmental Language Disorders

Clinical Outcomes of the ALPS Proximal Humerus Plating System

Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain.

The DETOUR 2 Clinical Trial

Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma

TT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors

Phase 1/2 Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)

A Study on Safety and Immune Response of Investigational RSV OA Vaccine in Combination With Herpes Zoster Vaccine in Healthy Adults

Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab

A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment

Study Using CABENUVA™ for the Treatment of Human Immunodeficiency Virus (HIV)-1, Administered in Infusion Centers (IC) or Alternate Sites of Administration (ASA) in the United States (U.S.)

XEN1101 for Major Depressive Disorder

EFS of Bioabsorbable Implant for NSD

A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS)